Discussing the Galleri Test and the Future of Cancer Screening on SuperAge

Recently, Dr. Amar Rewari was featured on *SuperAge*, where he shared his insights on a groundbreaking advancement in oncology: the Galleri multi-cancer early detection (MCED) test. In the feature, Dr. Rewari discussed the potential of this single blood test to identify methylation changes in cell-free DNA, which can signal more than 50 different types of cancer before symptoms even appear. 

While noting the promising data from trials like Pathfinder and the ongoing UK NHS Galleri trial, Dr. Rewari stressed a cautious and balanced approach. As he told *SuperAge*, "We're at the beginning of what could be a major shift in how we detect cancer — but right now, the Galleri test should complement, not replace, established screening methods." He also highlighted that, at this stage, the test is an out-of-pocket expense that should be used in consultation with a physician alongside standard preventative screenings.